Autoimmune Pancreatitis: Long-term Outcome

Autoimmune Pancreatitis: Long-term Outcome - Autoimmune Pancreatitis: Long-term Outcome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39923

Enrollment

Registered

2013-01-22

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Pancreatitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The following patients are eligible for the study: • All patients diagnosed with AIP according to the ICDC, Asian or HISORT criteria or based on post-surgery histology, a combination of unexplained pancreatic disease, biliary disease/extrapancreatic manifestations and either response to steroids or IgG4-positive serology. •At least known for more than 2 years with a diagnosis of AIP •Age > 18 years •Signed informed consent

Exclusion criteria

Exclusion criteria: The following patients are excluded from the study: •Subjects who are unwilling or unable to understand the study and sign the informed consent.

Design outcomes

Primary

Measure	Time frame
To determine the prevalence of exocrine and endocrine insufficiency in AIP patients.	—

Secondary

Measure	Time frame
To evaluate the following aspects of long-term outcome in AIP patients: i. Mortality and cause of death ii. Treatment over time: steroids, other drugs, response and relapses iii. Extrapancreatic manifestations of AIP/IgG4-related disease iv. Malignancy v. Morphology (including changes over time in case multiple imaging sets are available) of the pancreas on imaging vi. Quality of life	—

Countries

Netherlands

Outcome results